Development and Evaluation of CART Targeting Bcma with Humanized Alpaca-Derived Single-Domain Antibody As Antigen Recognition Domain
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-114980
Abstract: Chimeric antigen receptor T cells (CART) targeting CD19 have shown substantial activity against leukemia and lymphoma, which motivated developing CART cell therapy for Multiple myeloma (MM). B cell maturation antigen (BCMA) is the target molecule… read more here.
Keywords: cart; cart bcma; bcma; antibody ... See more keywords
PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-119514
Abstract: Background: Autologous T cells expressing a chimeric antigen receptor (CAR) specific for B-cell maturation antigen (CART-BCMA cells) show activity in refractory MM, but relapses remain common. Anti-PD-1 antibodies (Abs) augment CAR T cell activity pre-clinically,… read more here.
Keywords: cart bcma; research; consultancy; research funding ... See more keywords
Access and Outcomes of Minority Health Populations Receiving Commercial Anti-BCMA CART Therapy for Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-206544
Abstract: Background: Anti-BCMA chimeric antigen receptor T cell (CART-BCMA) immunotherapy is now a standard treatment for relapsed/refractory Multiple Myeloma (MM) after the first line. However, its widespread use might be limited by the need for access… read more here.
Keywords: cohort; cart bcma; mhp patients; cart ... See more keywords
CCR5 blockade: A therapeutic approach to uncouple CART-BCMA expansion from CART-mediated immune toxicities.
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-5945
Abstract: Introduction: Chimeric antigen receptor (CAR) T-cell therapy is standard care for relapsed or refractory hematologic malignancies. As clinical use expands, rare but serious toxicities beyond cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome… read more here.
Keywords: ccr5; cart bcma; cart; expansion ... See more keywords